Bosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March, 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.
Boschelli, Diane H.; Wang, Yanong D.; Johnson, Steve; Wu, Biqi; Ye, Fei; Sosa, Ana Carolina Barrios; Golas, Jennifer M.; Boschelli, Frank. 7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as Dual Inhibitors of Src and Abl Kinases. Journal of Medicinal Chemistry. Volume 47. Issue 7. Pages 1599-1601. Journal. (2004).
Mao, Yongjun; Zhu, Chunping; Kong, Ziyang; Wang, Jiao; Zhu, Guoqing; Ren, Xinfeng. New Synthetic Process for Bosutinib. Synthesis. Volume 47. Issue 20. Pages 3133-3138. Journal; Online Computer File. (2015).
Chen, Hong; Wang, Yingli; Liu, Tongbin. Synthesis of bosutinib. Zhongguo Yiyao Gongye Zazhi. Volume 44. Issue 11. Pages 1086-1088. Journal. (2013).
Wu, Yanchao; Jiang, Hong; Lv, Chuantao; Lu, Jingjing. Preparation method of Bosutinib using active copper reagent as coupling reaction catalytic reagent. Assignee Shandong Chuangxin Pharmaceutical Research & Development Co., Ltd., Peop. Rep. China. CN 109180578. (2019).
Xiao, Tao; Tian, Xin; Feng, Yi; Wang, Xiaoming; Li, Song. A process for preparing bosutinib. Assignee Nanjing Zhengrong Pharmaceutical Chemical Co., Ltd., Peop. Rep. China. CN 104876865. (2015).
